share_log

UnitedHealth Group's (NYSE:UNH) Soft Earnings Are Actually Better Than They Appear

UnitedHealth Group's (NYSE:UNH) Soft Earnings Are Actually Better Than They Appear

UnitedHealth Group(紐約證券交易所代碼:UNH)的軟收益實際上比看起來要好
Simply Wall St ·  04/25 19:03

UnitedHealth Group Incorporated's (NYSE:UNH) stock was strong despite it releasing a soft earnings report last week. We think that investors might be looking at some positive factors beyond the earnings numbers.

儘管上週發佈了疲軟的收益報告,但UnitedHealth Group Incorporated(紐約證券交易所代碼:UNH)的股票表現強勁。我們認爲,除了收益數字外,投資者可能會考慮一些積極因素。

earnings-and-revenue-history
NYSE:UNH Earnings and Revenue History April 25th 2024
紐約證券交易所:UNH 收益和收入歷史記錄 2024 年 4 月 25 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

To properly understand UnitedHealth Group's profit results, we need to consider the US$7.1b expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If UnitedHealth Group doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

爲了正確了解UnitedHealth Group的利潤業績,我們需要考慮歸因於不尋常項目的71億美元支出。看到不尋常的項目使公司利潤付出代價從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。鑑於這些單列項目被認爲不尋常,這並不奇怪。如果UnitedHealth Group不認爲這些不尋常的支出重演,那麼在其他條件相同的情況下,我們預計其利潤將在來年增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On UnitedHealth Group's Profit Performance

我們對UnitedHealth 集團利潤表現的看法

Unusual items (expenses) detracted from UnitedHealth Group's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that UnitedHealth Group's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing UnitedHealth Group at this point in time. To that end, you should learn about the 4 warning signs we've spotted with UnitedHealth Group (including 1 which makes us a bit uncomfortable).

去年,不尋常的項目(支出)減少了UnitedHealth Group的收益,但明年我們可能會看到改善。基於這一觀察,我們認爲UnitedHealth Group的法定利潤實際上可能低估了其盈利潛力!但不幸的是,其每股收益實際上在去年有所回落。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。因此,儘管收益質量很重要,但考慮UnitedHealth Group目前面臨的風險同樣重要。爲此,你應該了解我們在UnitedHealth Group發現的4個警告信號(其中一個讓我們有點不舒服)。

Today we've zoomed in on a single data point to better understand the nature of UnitedHealth Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單一數據點,以更好地了解UnitedHealth Group利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論